EPIRUS Biopharmaceuticals, Inc. - FORM 10-K - EX-23.1 - CONSENT OF ERNST & YOUNG LLP - March 26, 2010

Attached files

file filename
10-K - FORM 10-K - EPIRUS Biopharmaceuticals, Inc.d10k.htm
EX-21.1 - LIST OF SUBSIDIARIES - EPIRUS Biopharmaceuticals, Inc.dex211.htm
EX-32.1 - CERTIFICATION OF CEO & CFO PURSUANT TO SECTION 906 - EPIRUS Biopharmaceuticals, Inc.dex321.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - EPIRUS Biopharmaceuticals, Inc.dex312.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 302 - EPIRUS Biopharmaceuticals, Inc.dex311.htm
EX-10.54 - SUB-LEASE RENEWAL AND AMENDMENT AGREEMENT - EPIRUS Biopharmaceuticals, Inc.dex1054.htm
EX-10.56 - SECOND AMENDMENT TO LEASE AGREEMENT - EPIRUS Biopharmaceuticals, Inc.dex1056.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-131619, 333-135356 and 333-147745) of CombinatoRx, Incorporated of our report dated March 26, 2010, with respect to the consolidated financial statements of CombinatoRx, Incorporated included in this Annual Report (Form 10-K) for the year ended December 31, 2009.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 26, 2010

Stock widget

Investing forum

EPIRUS Biopharmaceuticals, Inc. Reports